SANDKI 360° powered by MIXMOVE
Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary healthcare products.
The network offers healthcare temperature-controlled transport for parcels and 1 to 5 pallet(s) shipments throughout 25 countries. Skandi Network is composed of 7 members who are all leading healthcare carriers. The main challenge of the network is to operate cross border transport shipments that involve cross docking operations.
“Having end-to-end visibility is already a challenge with one carrier but operating multi-county and multi-carrier operations at the same time is even more challenging. As we are transporting temperature sensitive healthcare products, we must guarantee that the products are transported in alignment with the GDP regulation and that temperature is monitored and always guaranteed. It is also important that our customers can have access to that information in real time.” -Rudy Smets, CEO of Skandi Network.
For these reasons, Skandi Network teamed up with MIXMOVE to develop a unique collaborative platform - Skandi 360° - to consolidate all operational and analytical data flows for all shipments going through the network.
One view and one access to the best-in-class healthcare transport network in Europe
Skandi Network is about giving access to the best-in-class healthcare transport network in Europe, working with 7 domestic leading freight forwarders. Skandi 360° will provide a coordinated solution to the market and its different stakeholders, giving them real time access and control of the first pan-European healthcare transport network (having over 4,780 vehicles and 165 temperature-controlled depots).
Connecting to Skandi 360° will allow them to expand, and/or optimise, their own capacities in a consolidated approach.
CO2 emissions reduction
In addition, Skandi 360° will also give an opportunity to reduce the carbon footprint and the cost of ownership throughout the whole transport chain. This includes:
- Consolidation of flows,
- Optimisation of logistics networks via regional distribution centres,
- No additional passive packaging needed in the network,
- And a reduction of damages and product loss during transport thanks to temperature monitoring.
Digitalising Logistics with MIXMOVE
MIXMOVE can integrate a very large amount of information and data coming from different sources and IT systems (like TMS, telematic systems, WMS, ERP). The MIXMOVE technology turns vertical and independent data flows into a flexible and consolidated One view/One access to data, all the way up to parcel/shipment level.
MIXMOVE also makes it possible to combine transport network functionalities and collaborative platform functionalities. This enables the management of the transport network in a lean and efficient way, creating real added value for all users of Skandi Network.
MIXMOVE tailors its technology to suit specific constraints linked to the healthcare transport business, including the regulations around integrating quality management, real-time temperature follow-up (including corrective and preventive actions), and POD’s that include an end-to-end temperature curve.
“We have chosen MIXMOVE for their proven expertise in the global supply chain and their proven technology to manage complex transport network operations. They use an advanced cloud-based technology with API connectivity. The MIXMOVE solution offers a capability to connect different systems and different tools (TMS, WMS, telematic systems…) seamlessly to the platform. This is what we needed, first to allow all members to be connected, and second to allow all external stakeholders, such as logistic service providers, to plug themselves into the platform and use our network." – Rudy Smets, CEO of Skandi Network.
About Skandi Network
Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary pharmaceuticals, biomedicals, APIs, temperature sensitive medical devices, diagnostics and general life products that are temperature sensitive. The network provides 2/8°C, 15/25°C and 20°C (in passive packaging) transport services and covers 25 countries thanks to the alliance of 7 leading healthcare carriers : Arra Group (Poland), BHS Logistics (Denmark, Sweden, Norway, Finland, Estonia, Latvia, Lithuania), BL Turkey Biopharma Logistics (Turkey), Eurotranspharma (France, Belgium, the Netherlands, Luxemburg, Spain, Czech Republic, Slovakia and also Germany, Austria and Slovenia via its existing local partner), Movianto (England, Scotland, Wales, Northern Ireland), PHSE (Italy), Rangel Logistics Solutions (Portugal). The aim of Skandi Network is to have members covering 36 countries by 2025. In total, the network members have more than 4,000 employees, operating in more than 4,780 temperature-controlled vehicles, 10 strategic regional consolidation platforms, 165 temperature controlled depots and transporting 14,750,000 temperature controlled shipments per year.
For more information : https://www.skandi-network.com/
About MIXMOVE
MIXMOVE provides a cloud solution supporting logistics by connecting systems, increasing profitability and reducing CO2 emissions.
For more than 10 years, MIXMOVE provides shippers, carriers and logistics service providers, the best customer experience in getting logistics transparency, predictability and resilience.
The main capabilities of the solution are focused on visibility, control and execution of transport & logistics services. Additional capabilities include optimising warehouse operations (like advanced cross-docking), order flow and fulfilment optimisation, planning automatisation, dispatching and routing optimisation.
MIXMOVE mobile applications enable digitalisation and collaboration with drivers. Trusted by customers like 3M, Volkswagen TPS, DHL, DSV, and Gebrüder Weiss, MIXMOVE has a proven track record in delivering high ROI, facilitating collaboration and helping achieve sustainability by improving resource utilisation.
For more information about MIXMOVE: www.mixmove.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005252/en/
Contact information
Rudy SMETS
CEO
mail@skandi-network.com
Dorothée DOSSMANN
Head of Marketing
dorothee.dossmann@mixmove.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom